Calithera Bio (CALA) Gets a Buy Rating from H.C. Wainwright


H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Calithera Bio (CALA) today and set a price target of $9.50. The company’s shares closed last Thursday at $3.73, close to its 52-week low of $2.99.

According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 3.4% and a 35.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Cellectar Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Calithera Bio with a $8.25 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $8.18 and a one-year low of $2.99. Currently, Calithera Bio has an average volume of 538.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Calithera Biosciences, Inc. engages in discovering and developing small molecule drugs that that target novel and critical metabolic pathway in tumor and cance-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Read More on CALA:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts